Dr. Guillermo Pérez Ishiwara is a Full Professor at the Molecular Biomedicine Laboratory, Instituto Politécnico Nacional (IPN), Mexico, and a member of the National System of Researchers (SNI Level III), the highest scientific distinction awarded in Mexico. He graduated with Honours from Universidad Nacional Autónoma de México (UNAM), where he received the Gabino Barreda Medal. He completed his MSc and PhD studies at CINVESTAV-IPN and later conducted a postdoctoral fellowship at the Bernhard Nocht Institute for Tropical Medicine in Hamburg, Germany.
Dr. Pérez Ishiwara’s research focuses on biopharmaceutics, tissue regeneration, precision medicine, and neurosciences. His laboratory develops innovative therapeutic strategies based on bioactive metabolites from Mexican medicinal plants, integrating nanotechnology to enhance pharmacological efficacy and reduce adverse effects. Current research includes novel therapeutics to prevent neurodegeneration associated with stroke, traumatic brain injury, and Parkinson’s disease, as well as bioactive systems for skin and gastric tissue regeneration.
His group also develops biosensors and bionanotechnology-based platforms for the early diagnosis of prostate and breast cancer, combining molecular biomedicine, nanotechnology, and translational research to generate innovative diagnostic and therapeutic solutions.
Dr. Guillermo Pérez Ishiwara is a Full Professor at the Molecular Biomedicine Laboratory, Instituto Politécnico Nacional (IPN), Mexico, and a member of the National System of Researchers (SNI Level III), the highest scientific distinction awarded in Mexico. He graduated with Honours from Universidad Nacional Autónoma de México (UNAM), where he received the Gabino Barreda Medal. He completed his MSc and PhD studies at CINVESTAV-IPN and later conducted a postdoctoral fellowship at the Bernhard Nocht Institute for Tropical Medicine in Hamburg, Germany.
Dr. Pérez Ishiwara’s research focuses on biopharmaceutics, tissue regeneration, precision medicine, and neurosciences. His laboratory develops innovative therapeutic strategies based on bioactive metabolites from Mexican medicinal plants, integrating nanotechnology to enhance pharmacological efficacy and reduce adverse effects. Current research includes novel therapeutics to prevent neurodegeneration associated with stroke, traumatic brain injury, and Parkinson’s disease, as well as bioactive systems for skin and gastric tissue regeneration.
His group also develops biosensors and bionanotechnology-based platforms for the early diagnosis of prostate and breast cancer, combining molecular biomedicine, nanotechnology, and translational research to generate innovative diagnostic and therapeutic solutions.